AC Immune SA opened lower at $2.21, compared with its previous close of $2.26. In the last trading session, the stock traded between $2.12 and $2.23. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in AC Immune SA is now worth
$ 35.37
Resulting in a loss of
$ 64.63 (64.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.12 (-5.31%)
Day High
$2.23
Day Low
$2.12
Day Open
$2.21
Prev Close
$2.26
Volume
1,07,609
1W Return
-5.93%
1M Return
-12.37%
3M Return
-15.58%
6M Return
-24.38%
1Y Return
-36.87%
Fundamentals
Market Cap ($ Mn)
218
PE Ratio
-
PB Ratio
6.09
PEG Ratio
-
ROE
-90.52%
ROCE
-77.38%
EPS (TTM)
$-0.09
Investment Returns
1 Week
-5.93%
1 Month
-12.37%
3 Months
-15.58%
6 Months
-24.38%
9 Months
-29.37%
Financials
Quarterly
All values in $ Mn
1.3
Jun 25
0.9
Sep 25
0.3
Dec 25
1.1
Mar 26
15.1
Jun 26
3.2
Sep 26
Updates
23Sep
AC Immune meets all primary endpoints in Parkinson's Phase 2 trial
All primary endpoints met in Part 1 of VacSYn Phase 2 trial for ACI-7104. 100% of treated patients developed antibodies against target antigen PD01. Robust antibody penetration into cerebrospinal fluid confirmed in all subjects. Company plans FDA meetings early 2027 to initiate Part 2 clinical activity trial.
1mo ago
20Aug
AC Immune reports positive Phase 1 data for NLRP3 inhibitor ACI-19764
AC Immune reports positive Phase 1 data for NLRP3 inhibitor ACI-19764. Drug showed no serious adverse events at doses up to 20mg daily. Brain penetration confirmed via cerebrospinal fluid exposure. Phase 1b dosing started in patients with cardiovascular disease risk.
2mo ago
7Jul
AC Immune presents Morphomer data at AAIC
AC Immune presented three studies at the Alzheimer's Association International Conference (AAIC) from July 12 to July 15, showcasing its Morphomer-based small molecule approach. Key assets include a first-in-class TDP-43 PET tracer with early human imaging data in FTD and ALS, a Phase 1 brain-penetrant NLRP3 inhibitor, and an alpha-synuclein aggregation inhibitor. These findings support the development of biomarker-led therapies for neurodegenerative diseases.
4mo ago
30Jun
AC Immune interim data shows ACI-24 safety in Alzheimer’s trial
AC Immune SA reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24, demonstrating general safety and tolerability with no ARIA-E in 74 patients. The company initiated Cohort AD4 to evaluate ACI-24 with an additional adjuvant to boost immunogenicity.
4mo ago
11Jun
AC Immune secures $4M grant for Parkinson's trial extension
AC Immune SA has secured a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its Phase 2 VacSYn trial for ACI-7104 in early Parkinson's disease. The grant supports a two-year extension to evaluate long-term safety and efficacy, building on positive interim results from December 2025. Final data from the trial is anticipated in H2 2026.
